Hergenroeder, Georgene W. http://orcid.org/0000-0002-6170-2191
Yokobori, Shoji
Choi, Huimahn Alex
Schmitt, Karl
Detry, Michelle A.
Schmitt, Lisa H.
McGlothlin, Anna
Puccio, Ava M.
Jagid, Jonathan
Kuroda, Yasuhiro
Nakamura, Yukihiko
Suehiro, Eiichi
Ahmad, Faiz
Viele, Kert
Wilde, Elisabeth A.
McCauley, Stephen R.
Kitagawa, Ryan S.
Temkin, Nancy R.
Timmons, Shelly D.
Diringer, Michael N.
Dash, Pramod K.
Bullock, Ross
Okonkwo, David O.
Berry, Donald A.
Kim, Dong H.
Funding for this research was provided by:
The Vivian L. Smith Foundation for Neurologic Research
JSPS KAKENHI Grant-in-Aid for Scientific Research (JP26293386)
ZOLL Circulation, Inc.
NIH/NCATS (UL1 TR000445, UL1 TR001105 and UL1 TR000371)
Article History
Received: 7 April 2021
Accepted: 13 August 2021
First Online: 13 September 2021
Declarations
:
: The authors declare that they have no conflicts of interest to disclose except for the following: Donald Berry is co-owner of Berry Consultants, a company that designs adaptive Bayesian clinical trials for pharmaceutical and medical device companies, National Institutes of Health cooperative groups, patient advocacy groups, and international consortia.
: The study adheres to ethical guidelines and indicates ethical approvals and use of informed consent, as appropriate.
: This trial was registered in ClinicalTrials.gov as NCT02064959, and UMIN000014863 in the Japanese University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN-CTR)ExternalRef removed.